The validity and significance of substages of advanced ovarian cancer

Edward E. Partridge, Brett C. Gunter, Mark S. Gelder, Ronald D. Alvarez, Seno Jaw Soong, J. Maxwell Austin, Larry Kilgore

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

No studies to date have evaluated the validity of the new FIGO substaging of advanced epithelial ovarian cancer nor assessed the importance of substage in relation to other elements such as age at diagnosis, debulking surgery, and second-look laparotomy. The purpose of this study was to determine the significance of these factors. One hundred sixty-seven patients with Stage III ovarian cancer were restaged according to the 1988 FIGO criteria (6% Stage IIIa, 15.6% Stage IIIb, and 78.4% Stage IIIc). The mean age at diagnosis was 40.5 for Stage IIIa, 51 for Stage IIIb, and 62 for Stage IIIc (P = 0.0001). Median survival was 2.5 years for patients age <60 and 1.4 years for those age ≥60 (P = 0.0001). Median survival for patients undergoing TAH/BSO was 2.06 years, bowel resection 1.39 years, and biopsy only 1.38 years (P = 0.0003). Only 61 of 131 Stage IIIc patients underwent second-look laparotomy. Seven of nine Stage IIIa, 6 of 17 Stage IIIb, and 14 of 61 Stage IIIc patients had negative second-look laparotomies (P = 0.004). Only 4 of the 14 patients with Stage IIIc and 8 of 13 Stage IIIa/b patients are alive after negative second look (P = 0.37). Median survival for Stage IIIa patients has not been reached and for Stages IIIb and IIIc was 2.29 years and 1.33 years, respectively (P = 0.0001). These data confirm the prognostic validity of FIGO substages for Stage III. The age differential by substages suggests that the natural history of Stage III disease is progressive over several decades. The appropriateness of aggressive cytoreductive surgery and second-look laparotomy must be reevaluated using the new FIGO staging system.

Original languageEnglish (US)
Pages (from-to)236-241
Number of pages6
JournalGynecologic oncology
Volume48
Issue number2
DOIs
StatePublished - Jan 1 1993

Fingerprint

Ovarian Neoplasms
Laparotomy
Second-Look Surgery
Survival
Natural History
Biopsy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynecology

Cite this

Partridge, E. E., Gunter, B. C., Gelder, M. S., Alvarez, R. D., Soong, S. J., Austin, J. M., & Kilgore, L. (1993). The validity and significance of substages of advanced ovarian cancer. Gynecologic oncology, 48(2), 236-241. https://doi.org/10.1006/gyno.1993.1040

The validity and significance of substages of advanced ovarian cancer. / Partridge, Edward E.; Gunter, Brett C.; Gelder, Mark S.; Alvarez, Ronald D.; Soong, Seno Jaw; Austin, J. Maxwell; Kilgore, Larry.

In: Gynecologic oncology, Vol. 48, No. 2, 01.01.1993, p. 236-241.

Research output: Contribution to journalArticle

Partridge, EE, Gunter, BC, Gelder, MS, Alvarez, RD, Soong, SJ, Austin, JM & Kilgore, L 1993, 'The validity and significance of substages of advanced ovarian cancer', Gynecologic oncology, vol. 48, no. 2, pp. 236-241. https://doi.org/10.1006/gyno.1993.1040
Partridge EE, Gunter BC, Gelder MS, Alvarez RD, Soong SJ, Austin JM et al. The validity and significance of substages of advanced ovarian cancer. Gynecologic oncology. 1993 Jan 1;48(2):236-241. https://doi.org/10.1006/gyno.1993.1040
Partridge, Edward E. ; Gunter, Brett C. ; Gelder, Mark S. ; Alvarez, Ronald D. ; Soong, Seno Jaw ; Austin, J. Maxwell ; Kilgore, Larry. / The validity and significance of substages of advanced ovarian cancer. In: Gynecologic oncology. 1993 ; Vol. 48, No. 2. pp. 236-241.
@article{94a4ec5eea0147729828db3f18eb07b7,
title = "The validity and significance of substages of advanced ovarian cancer",
abstract = "No studies to date have evaluated the validity of the new FIGO substaging of advanced epithelial ovarian cancer nor assessed the importance of substage in relation to other elements such as age at diagnosis, debulking surgery, and second-look laparotomy. The purpose of this study was to determine the significance of these factors. One hundred sixty-seven patients with Stage III ovarian cancer were restaged according to the 1988 FIGO criteria (6{\%} Stage IIIa, 15.6{\%} Stage IIIb, and 78.4{\%} Stage IIIc). The mean age at diagnosis was 40.5 for Stage IIIa, 51 for Stage IIIb, and 62 for Stage IIIc (P = 0.0001). Median survival was 2.5 years for patients age <60 and 1.4 years for those age ≥60 (P = 0.0001). Median survival for patients undergoing TAH/BSO was 2.06 years, bowel resection 1.39 years, and biopsy only 1.38 years (P = 0.0003). Only 61 of 131 Stage IIIc patients underwent second-look laparotomy. Seven of nine Stage IIIa, 6 of 17 Stage IIIb, and 14 of 61 Stage IIIc patients had negative second-look laparotomies (P = 0.004). Only 4 of the 14 patients with Stage IIIc and 8 of 13 Stage IIIa/b patients are alive after negative second look (P = 0.37). Median survival for Stage IIIa patients has not been reached and for Stages IIIb and IIIc was 2.29 years and 1.33 years, respectively (P = 0.0001). These data confirm the prognostic validity of FIGO substages for Stage III. The age differential by substages suggests that the natural history of Stage III disease is progressive over several decades. The appropriateness of aggressive cytoreductive surgery and second-look laparotomy must be reevaluated using the new FIGO staging system.",
author = "Partridge, {Edward E.} and Gunter, {Brett C.} and Gelder, {Mark S.} and Alvarez, {Ronald D.} and Soong, {Seno Jaw} and Austin, {J. Maxwell} and Larry Kilgore",
year = "1993",
month = "1",
day = "1",
doi = "10.1006/gyno.1993.1040",
language = "English (US)",
volume = "48",
pages = "236--241",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - The validity and significance of substages of advanced ovarian cancer

AU - Partridge, Edward E.

AU - Gunter, Brett C.

AU - Gelder, Mark S.

AU - Alvarez, Ronald D.

AU - Soong, Seno Jaw

AU - Austin, J. Maxwell

AU - Kilgore, Larry

PY - 1993/1/1

Y1 - 1993/1/1

N2 - No studies to date have evaluated the validity of the new FIGO substaging of advanced epithelial ovarian cancer nor assessed the importance of substage in relation to other elements such as age at diagnosis, debulking surgery, and second-look laparotomy. The purpose of this study was to determine the significance of these factors. One hundred sixty-seven patients with Stage III ovarian cancer were restaged according to the 1988 FIGO criteria (6% Stage IIIa, 15.6% Stage IIIb, and 78.4% Stage IIIc). The mean age at diagnosis was 40.5 for Stage IIIa, 51 for Stage IIIb, and 62 for Stage IIIc (P = 0.0001). Median survival was 2.5 years for patients age <60 and 1.4 years for those age ≥60 (P = 0.0001). Median survival for patients undergoing TAH/BSO was 2.06 years, bowel resection 1.39 years, and biopsy only 1.38 years (P = 0.0003). Only 61 of 131 Stage IIIc patients underwent second-look laparotomy. Seven of nine Stage IIIa, 6 of 17 Stage IIIb, and 14 of 61 Stage IIIc patients had negative second-look laparotomies (P = 0.004). Only 4 of the 14 patients with Stage IIIc and 8 of 13 Stage IIIa/b patients are alive after negative second look (P = 0.37). Median survival for Stage IIIa patients has not been reached and for Stages IIIb and IIIc was 2.29 years and 1.33 years, respectively (P = 0.0001). These data confirm the prognostic validity of FIGO substages for Stage III. The age differential by substages suggests that the natural history of Stage III disease is progressive over several decades. The appropriateness of aggressive cytoreductive surgery and second-look laparotomy must be reevaluated using the new FIGO staging system.

AB - No studies to date have evaluated the validity of the new FIGO substaging of advanced epithelial ovarian cancer nor assessed the importance of substage in relation to other elements such as age at diagnosis, debulking surgery, and second-look laparotomy. The purpose of this study was to determine the significance of these factors. One hundred sixty-seven patients with Stage III ovarian cancer were restaged according to the 1988 FIGO criteria (6% Stage IIIa, 15.6% Stage IIIb, and 78.4% Stage IIIc). The mean age at diagnosis was 40.5 for Stage IIIa, 51 for Stage IIIb, and 62 for Stage IIIc (P = 0.0001). Median survival was 2.5 years for patients age <60 and 1.4 years for those age ≥60 (P = 0.0001). Median survival for patients undergoing TAH/BSO was 2.06 years, bowel resection 1.39 years, and biopsy only 1.38 years (P = 0.0003). Only 61 of 131 Stage IIIc patients underwent second-look laparotomy. Seven of nine Stage IIIa, 6 of 17 Stage IIIb, and 14 of 61 Stage IIIc patients had negative second-look laparotomies (P = 0.004). Only 4 of the 14 patients with Stage IIIc and 8 of 13 Stage IIIa/b patients are alive after negative second look (P = 0.37). Median survival for Stage IIIa patients has not been reached and for Stages IIIb and IIIc was 2.29 years and 1.33 years, respectively (P = 0.0001). These data confirm the prognostic validity of FIGO substages for Stage III. The age differential by substages suggests that the natural history of Stage III disease is progressive over several decades. The appropriateness of aggressive cytoreductive surgery and second-look laparotomy must be reevaluated using the new FIGO staging system.

UR - http://www.scopus.com/inward/record.url?scp=0027476280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027476280&partnerID=8YFLogxK

U2 - 10.1006/gyno.1993.1040

DO - 10.1006/gyno.1993.1040

M3 - Article

VL - 48

SP - 236

EP - 241

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -